BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32599983)

  • 1. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
    Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
    Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
    Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.
    Shen YY; Lu YC; Shen DP; Liu YJ; Su XY; Zhu GS; Yin XL; Ni XZ
    World J Gastroenterol; 2013 Jul; 19(28):4568-75. PubMed ID: 23901234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
    Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
    Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
    Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
    World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
    Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
    Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
    Di Giorgio C; Bellini R; Lupia A; Massa C; Urbani G; Bordoni M; Marchianò S; Rosselli R; De Gregorio R; Rapacciuolo P; Sepe V; Morretta E; Monti MC; Moraca F; Cari L; Ullah KRS; Natalizi N; Graziosi L; Distrutti E; Biagioli M; Catalanotti B; Donini A; Zampella A; Fiorucci S
    Cell Oncol (Dordr); 2024 Apr; 47(2):695-710. PubMed ID: 37945798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
    Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
    Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
    Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
    World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.
    Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
    Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
    Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
    Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
    Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.
    Xu B; Tong N; Chen SQ; Hua LX; Wang ZJ; Zhang ZD; Chen M
    BMC Cancer; 2011 Feb; 11():84. PubMed ID: 21349172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.
    Wimmer E; Ihrler S; Gires O; Streit S; Issing W; Bergmann C
    World J Clin Oncol; 2019 Mar; 10(3):136-148. PubMed ID: 30949443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer.
    Li L; Cui Y; Ye L; Zhao Z; Jiang WG; Ji J
    Int J Oncol; 2018 Sep; 53(3):1171-1182. PubMed ID: 29956751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
    Whittle SB; Reyes S; Du M; Gireud M; Zhang L; Woodfield SE; Ittmann M; Scheurer ME; Bean AJ; Zage PE
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):131-8. PubMed ID: 26840079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is FGFR4 Gly388Arg missense variant a suitable prognostic marker in neuroblastoma?
    Katarzyna S
    J Cancer Res Ther; 2023; 19(2):355-358. PubMed ID: 37006072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
    Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
    Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of CD44v6 expression in gastric carcinoma by the IL-6/STAT3 signaling pathway and its clinical significance.
    Xu YY; Guo M; Yang LQ; Zhou F; Yu C; Wang A; Pang TH; Wu HY; Zou XP; Zhang WJ; Wang L; Xu GF; Huang Q
    Oncotarget; 2017 Jul; 8(28):45848-45861. PubMed ID: 28507278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.